The airway retention of inhaled glucocorticosteroids (GCs) depends largely on their lipophilicity. Inhaled budesonide (BUD) becomes highly lipophilic reversibly by the formation of esters, acting as a reservoir of active BUD. Ciclesonide (CIC) was also reported to form esters after hydrolysis to active metabolite (CIC-AM). We have investigated lipophilicity and airway retention of BUD, CIC/CIC-AM, fluticasone propionate (FP) and mometasone furoate (MF), and compared esterification of BUD and CIC-AM and its contribution to GC airway retention. Rat tracheas were preincubated with the esterification inhibitor cyclandelate or vehicle. A 3 H-GC (~10 -7 M: BUD, CIC, CIC-AM, FP, MF) was added for 20 min. After incubation, one half of trachea was used for analysis of GC uptake and the other to analyse GC release during 3 hours in drug-free medium. GC species in trachea halves were analysed by radiochromatography. At 20 min the uptake of BUD was similar to CIC/CIC-AM, however BUD-ester pool was 9-fold greater (p<0.01). BUD overall retention in trachea at 3 hours was greater than other GCs (p<0.01), and BUD-ester pool was 3-fold greater than CIC-AM-ester pool (p<0.01).
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Introduction
Lipophilicity is an important physicochemical property of inhaled glucocorticosteroids (GCs) affecting their tissue kinetics and activity. High lipophilicity increases both the GC uptake and retention in airway tissue (i.e. decelerates removal of GCs from airway tissue), and thereby enhances and prolongs anti-inflammatory efficacy of inhaled GCs in the airways (Brattsand,1997) . On the other hand, high lipophilicity can be a disadvantage in the peripheral tissues leading to enhanced distribution and retention, prolonged terminal plasma half-life, and accumulation (Thorsson et al., 1997, and Lipworth and Jackson, 2000) . Furthermore, highly lipophilic inhaled GCs have a low water solubility which may increase the GC fraction that is cleared by mucocilliary escalator before it is dissolved in airway fluid and absorbed into airway tissue and becomes available for cytosolic GC receptor (Edsbäcker, 2002) . Therefore, the "ideal" inhaled GC might be one with "transformable" lipophilicity, that is, moderate lipophilicity in airway lumen, high lipophilicity when taken up into the airway tissue, and low lipophilicity during systemic distribution (Brattsand,1999) .
Beclomethasone dipropionate (BDP), fluticasone propionate (FP) and recently introduced mometasone furoate (MF) are examples of highly lipophilic inhaled GCs. After absorption from the airway lumen, BDP is converted to a less lipophilic, active metabolite, beclomethasone monopropionate (BMP), whereas lipophilicity of FP and MF does not change during the passage from the airway lumen to systemic distribution. In contrast to these GCs, inhaled budesonide (BUD) has a moderate lipophilicity but in airway tissue it becomes esterified with fatty acids forming a highly lipophilic depot of reversible BUD esters that act as a reservoir of active BUD (Miller-Larsson et al., 1998) .
This article has not been copyedited and formatted. The final version may differ from this version. After inhalation, more than 50% of total BUD retained in the rat and human bronchial, nasal and lung tissue is esterified at the carbon-21-hydroxyl group, primarily as BUD oleate (Miller-Larsson et al.,1998; Jendbro et al., 2001; Petersen et al., 2001; Thorsson et al., 1998; Maasen van den Brink et al., 2005) . BUD esters are not active i.e. do not bind to glucocorticoid receptor (Wieslander et al., 1998) but they are hydrolysed slowly, gradually releasing active BUD (Wieslander et al., 1998; Miller-Larsson et al., 1998) . The formation of BUD esters prolongs the retention and activity of a BUD pulse in rat fibroblast cell line (Wieslander et al., 1998, and , and esterification of BUD in the airways likely explains the very well documented once daily efficacy of inhaled BUD (Campbell et al., 1991; Jones et al., 1994; Banov et al., 2001; Selroos et al., 2004) .
Theoretically, other GCs with hydroxyl group at carbon-21 can be esterified in a similar way to BUD. These include an endogenous GC -corticosterone and a synthetic GC -BMP. However, esterification of corticosterone seems not to play a role in corticosterone tissue kinetics and biological activity, probably because corticosterone esters are hydrolysed rapidly (Hochberg et al., 1991) . Rapid hydrolysis may also explain why BMP esters were not found in rat airways and lungs (Miller-Larsson et al., 1998) .
Recently, a new inhaled GC, ciclesonide (CIC), was introduced. CIC is inactive but it is hydrolysed to an active metabolite (CIC-AM) that was reported to form fatty acid esters in airway tissue. CIC-AM esters have been detected in vitro in human alveolar and nasal epithelial cells (Nave et al., 2005a (Nave et al., , 2006a and in rat and human lung slices (Nave et al., 2004, and 2006b ). They were also detected after inhalation of CIC in rat and human lungs (Nave et al., 2005b; Watz et al., 2006) . However, the experience from corticosterone suggests that formation of esters alone may not be sufficient to affect the tissue kinetics of the GCs. There is no information on the role of CIC-AM esterification on the retention of CIC-AM in the airways, and once daily efficacy of CIC (Chapman et al., 2005; Pearlman et al., 2005) (Nayak et al., 2000; Karpel et al., 2005) although it does not form esters.
Therefore, in this study, in a rat trachea model, we have compared airway retention of CIC/CIC-AM and CIC-AM esterification to those of BUD, and determined CIC and CIC-AM lipophilicity in relation to BUD. As a reference, and to validate the system, we have used FP and MF, which do not form esters.
This article has not been copyedited and formatted. The final version may differ from this version. Radiochemical purity was at least 98.0%. Cyclandelate was purchased from TCI Tokyo Kasei (Tokyo, Japan) or Sigma-Aldrich (Cat# C-9260) (Stockholm, Sweden).
Determination of GC water solubility and lipophilicity
Water solubility. The water solubility of GCs was determined by mixing 1 mg of the GC powder and 5 ml Milli-Q water. The slurry was sonicated for 5 min and left on a shaker for 17 h. The sample was then filtered through a 0.45 µm Millipore Millex HV filter (Millipore, Billerica, MA,USA). The concentration in the filtrate was determined by high performance liquid chromatography (HPLC) using a Supelcosil LC-18 column (Supelco Belefonte, PA, USA), 150x4.6 mm. The flow rate was 1.0 ml/min of a mixture of acetonitrile and water, 72/28 for CIC and 47/53 for all other GCs. The GC concentration was calculated using a reference standard for each GC. The limit of quantification at 254 nm was determined to 0.1 µg/ml.
In the analysis of water solubility of MF there was a second peak in the chromatogram, approximately 30% of the size of the MF, which may indicate a degradation of MF.
However, the actual value measured for the MF solubility was 0.03 µg/ml, which was For the purpose of this paper, the low limit of quantitation was set to 0.1 µg/ml and thus a possible stability problem of MF did not affect the result on water solubility reported.
Lipophilicity. The relative lipophilicity of GCs was estimated by the chromatographic capacity factor log k'(0). The capacity factor, k', was determined as k'=(t R -t 0 )/t 0 were t R is the retention time for the analyte and t 0 is the retention time for a non-retained analyte, e.g. KNO 3 , in a given liquid chromatography system. The retention time for each analyte in the HPLC system described above for water solubility was determined for at least four different concentrations of acetonitrile in the range of 30-70%. For each analyte the log k'
values were calculated and plotted against organic content giving linear relation; the correlation coefficient value (R 2 ) for was each analyte > 0.99. From this, the value of log k'(0), i.e. k' at 0% organic phase, was extrapolated. For structurally related compounds it has been shown that log k'(0) is a good representation of the log P value i.e.
octanol/water distribution (Tsantili-Kakoulidou et al., 1993; Rothemund et al., 1994; Yamagami et al., 2002) .
Study design
Study design is shown in Fig.1 . Tracheal segments from Brown Norway rats were dissected (approximately 50 mg) and placed in cold standard oxygenated Krebs buffer. A lengthwise incision through the cartilage of the trachea was made and trachea was tied to a glass rod and immersed in 10 ml medium consisted of standard Krebs buffer with 0.2% glucose and 10% autologous rat plasma (to approximate the protein concentration of airway epithelial lining fluid; Robinson et al., 1989 H-GC tissue concentrations before (initial uptake) and after 3 hour-release.
The total radioactivity of tissue extracts was measured by liquid scintillation counting, and GC species in tissue extracts were analysed by radiochromatography.
H-GC preparation
For all GCs except FP, 50 
Cyclandelate preparation
Cyclandelate was suspended in 99.5% ethanol to a concentration of 55.3 mg/ml (2x10 
Analysis of GC species in tracheal extracts
Trachea extracts were prepared by microwave assisted extraction in 2 ml 99.5% ethanol GC species were identified and confirmed in pilot experiments applying liquid chromatography and mass spectroscopy techniques using HP1100 LC system (Agilent Technologies, Waldbronn, Germany) in line with a QTOF mass spectrometer (Waters, Manchester, UK). The identification was based on comparison of chromatographic retention times of reference compounds and mass spectrometry data.
Data Analysis
The tissue concentration (Q) of GC species in the samples, expressed as picomoles/gram (pmol/g), was calculated from the following equation: Q = DPM x DF/(C x SA x W), where DPM is the mean number of disintegrations per minute (dpm) measured in the sample, DF is dilution factor (=4, total extract volume/LC injection volume), C = 2.22 x 10 6 dpm per microCurie (µCi,) SA is the specific radioactivity of GC applied (µCi per picomoles), and W is the weight (grams) of tissue samples. As the 3 H-GC concentrations in incubation medium differed somewhat between GCs (see Study Design), Q values were normalised to the concentration of 1.0x10 -7 M and expressed as pmol/g. When two or more species of a GC were detected, the sum of their Q values was calculated, and is referred here as the total tissue concentration of a GC in trachea.
Statistical analysis
Data are presented as arithmetic means ± SEM. Data were analysed by one-way analysis of variance ANOVA with significance level down to 1% using Astute software 1.5
(DDU Software, Leed, UK). Differences were considered significant at p<0.05.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Water solubility and lipophilicity of GCs
The relative lipophilicitiy and water solubility for the inhaled GCs: BUD, FP, MF and CIC/CIC-AM were determined and are presented in the Table 1 .
Tissue uptake and retention of GCs
Radiochromatographic analysis of trachea extracts revealed fractions of active GCs, GC esters, and parent GC (for CIC). In experiments with BUD or CIC-AM, unmodfied GCs and GC esters were detected ( Fig. 2A-D) . In experiments with CIC, three fractions were detected: parent CIC, CIC-AM and CIC-AM esters ( (Fig. 3) . Thus, at 20 min a 2-fold higher concentration of these GCs was attained in tracheal tissue than GC concentration present in the incubation medium. The exception was FP, which reached 5-fold higher tissue concentration than the level in the medium (Fig. 3) . Uptake of FP into tracheal tissue was 2-fold higher than that of total BUD (p<0.01), whereas uptake of MF was 34% lower than that of total BUD (p<0.05). The total CIC/CIC-AM tracheal concentrations were 20-25% lower than that of BUD but these differences were not statistically significant (Fig. 3) .
The retention of GCs in tracheal tissue was determined by the percentage of the total tracheal concentration of a GC remained after the 3 hour-incubation of trachea in GC- Fig. 3 ). We have shown earlier in this system that only the intact BUD (and not BUD esters) is released from trachea into incubation medium (Miller-Larsson et al., 1998) . Similarly, only CIC and CIC-AM, but not CIC-AM esters, were detected in medium after incubation with human lung slices (Nave et al., 2006c) .
Analysis of esterified species in trachea revealed that a much higher percentage of BUD was in the esterified form than for the CIC/CIC-AM (Fig. 4) . After the 20 min incubation, BUD esters made up 46% of the total BUD content in trachea whereas CIC-AM esters made up 6-7% of the total CIC content (p<0.01 versus BUD) after both CIC or CIC-AM incubation. After the subsequent 3 hour-release period in GC-free medium, BUD esters made up 92% of the total BUD as compared to 52% or 67% of CIC-AM esters after incubation with CIC or CIC-AM, respectively (p<0.01 for both versus BUD). In the absolute amounts, the BUD-ester pool was 9-fold greater than the CIC-AM-ester pool after 20 min incubation (p<0.01), and 3-fold greater after the 3 hour-release period (p<0.01). These results show that BUD was esterified in trachea more promptly and to a greater extent than CIC-AM.
Role of GC esterification for tissue uptake and retention of GCs
The relationship between esterification and retention of BUD, CIC and CIC-AM was Incubation with cyclandelate significantly decreased the initial BUD-ester pool in trachea to 31% of vehicle-treated value (p<0.01), and increased the pool of BUD 1.8-fold (p<0.01) but it did not affect the total BUD uptake at 20 min (1.1-fold increase, p=0.2) (Fig. 6) . Similarly, incubation of CIC-AM with cyclandelate significantly decreased CIC-AM esters to 6% of vehicle-treated value (p<0.01), and increased the pool of CIC-AM 2-fold (p<0.01), but it also significantly increased 1.9-fold (p<0.01) the total uptake of CIC-AM at 20 min (Fig. 6 ). The uptake of MF was not affected by cyclandelate, while the uptake of FP was reduced by 19%, but this difference was not statistically significant (p=0.1; data not shown).
Although cyclandelate was discontinued before the 3 hour-release period (and trachea was briefly washed in fresh buffer), cyclandelate accelerated and increased BUD release during 3 hour-incubation period in drug-free medium (without GC and cyclandelate). In consequence, the total BUD remained in trachea after this period was significantly lower than BUD remained under control conditions (i.e. without cyclandelate) ( Fig. 7A and C) .
In contrast, cyclandelate did not affect the retention of CIC-AM (which forms esters) ( Fig   7B and C) nor of FP and MF (which cannot form esters) (Fig. 7C) . Under control conditions, the release of BUD from trachea was significantly slower than those for all other GCs tested, and cyclandelate abolished this difference (Fig. 7C) . Thus, reduction of BUD-ester pool at 20 min significantly decreased total retention of BUD after 3 hourrelease period. These results give evidence that BUD retention in tracheal tissue is prolonged due to formation of BUD esters.
Discussion
We have demonstrated in a rat trachea in vitro model, the prolonged overall retention of BUD in tracheal tissue compared to more lipophilic FP, MF and CIC/CIC-AM. The prolonged retention of BUD was due to the endogenous formation of BUD fatty acid esters, as it was reduced to the level of other GCs when formation of BUD esters was inhibited. BUD was esterified more promptly and to a greater extent than CIC-AM. In contrast to BUD, the nearly complete inhibition of the intitial CIC-AM-ester pool did not reduce retention of CIC-AM. These results suggest that the airway retention of CIC-AM is not dependent on CIC-AM esterification but may be mainly determined by high lipophilicity of CIC-AM and parent CIC, similarly to FP and MF that are not esterified.
The uptake of BUD into rat tracheal tissue was roughly comparable to the uptake of either CIC or CIC-AM. The absolute total tissue concentration of these GCs reached in trachea after 20 min incubation was at the level of ~10 -7 M (10 -7 mol/kg). Similar tissue concentrations in rat trachea, and a 10-fold lower level in lung tissue, were earlier obtained in vivo after inhalation of BUD and FP (Miller-Larsson et al., 1998) and recently after inhalation of CIC (Watz et al., 2006) . The ~10 -8 M concentration in lung tissue corresponds to the levels obtained in humans 1-4 hours after inhalation of high clinical doses (1-2 mg) of GCs (Van den Bosch et al., 1993; Esmailpour et al., 1997; Thorsson et al., 1998; Maassen van den Brink et al., 2005; Watz et al., 2006) .
The experiments on in vitro uptake of GCs were conducted with 10% autologous rat serum in the incubation medium. This concentration was chosen to approximate the protein concentration present in airway lining fluid. The protein amount in airway lining fluid is difficult to measure, and it is known to increase in inflammation and certain airway diseases, but we decided to use a conservatively low value for these experiments (Robinson et al., 1989) . This is an important technical consideration, because the tissue concentrations. CIC and CIC-AM bind to plasma proteins at ∼99% (Rohatagi et al., 2005) as compared to 88% binding of BUD (Ryrfeldt et al., 1982) . Accordingly, Jerre et al. instilled intratracheally into rats, the uptake of BUD into both trachea and lung tissue was higher than CIC (Gullstrand et al., 2005) . It is conceivable that besides the initial uptake, also the tissue retention of GCs with high protein binding can be increased by using too low protein concentration in the incubation medium in in vitro experiments.
Despite roughly equal uptake of BUD and CIC/CIC-AM into rat trachea in the present study, there were two major differences in tracheal tissue kinetics between BUD and CIC/CIC-AM. The first one was that a much larger proportion of BUD than of CIC-AM was esterified within the 20 min and remained esterified after the 3 hour-release period.
Similarly, in an above mentioned in vivo study, where rats were instilled intratracheally with BUD or CIC, BUD retained in trachea tissue was esterified to a significantly greater extent than CIC-AM (and in contrast to BUD esters, CIC-AM esters were not detectable in lung tissue; Gullstrand et al., 2005) . In the present study, to investigate CIC-AM (Tunek et al., 1997) . It was earlier shown that cyclandelate, an inhibitor of ACAT, decreased the amount of BUD esters and shortened the retention and activity of BUD pulse in rat fibroblast cell line (Wieslander et al., 2000) . In the present study we have confirmed and extended these findings demonstrating that reduction of the initial BUD-ester pool by cyclandelate significantly decreased retention of BUD in rat tracheal tissue at 3 hours. Cyclandelate treatment also nearly completely blocked the initial CIC-AM-ester pool, however in contrast to BUD, it did not decrease the retention of CIC-AM in rat trachea at 3 hours.
It was not expected that cyclandelate should affect tissue kinetics of FP or MF in trachea, and it had no effect on either their uptake or retention, which validates the system. The retention of FP and MF in trachea was similar to those of CIC and CIC-AM (Fig. 7) . FP, MF, CIC and CIC-AM are all highly lipophilic GCs (Table 1) , and high lipophilicity was shown to increase the airway retention of inhaled GCs (Brattsand, 1997) . The very high lipophilicity of BUD esters (Table 1) , rapidly formed in the airways, retards absorption of BUD into blood circulation and explains the prolonged airway retention of inhaled BUD.
The major CIC-AM ester, oleate, was reported to be 5 times more lipophilic than BUD oleate (Nave et al., 2004) . However, a slow rate of net formation of CIC-AM esters probably explains the finding that the blockage of the initial small pool of CIC-AM esters did not prolong CIC-AM retention in trachea in the present study. It seems that after Surprisingly, the presence of cyclandelate significantly increased nearly 2-fold the initial uptake of CIC-AM but not that of BUD or other GCs tested. This is despite that CIC-AM esters initially made up only 6-7% of the total CIC-AM in tracheal tissue while BUD esters made up nearly 50% of the total BUD. We do not have explanation for the increased uptake of CIC-AM by cyclandelate. Furthermore, we have expected that the blockage of BUD esterification will decrease BUD uptake as it was shown in rat fibroblast cell line (Wieslander et al., 2000) . The finding that the BUD uptake into tracheal tissue was not dependent on BUD esterification and was roughly equal to that of the 2-4 times more lipophilic MF, CIC-AM and CIC, but lower than the 3-fold more lipophilic FP, suggests that besides lipophilicity there are other factors which influence GC uptake into airway tissue. For example, evidence is growing that cellular concentrations of GCs are regulated not only by GC passive diffusion, dependent on small size and high lipophilicity of GC molecules, but also via efflux transporters, such as P-glycoprotein. The efficiency of P-glycoprotein-mediated efflux of various GCs seems to depend on subtle differences in GC structure (Yates et al., 2003) . Recent data in colon carcinoma cells suggest that BDP, MF and CIC-AM, but not FP, are substrates to P-glycoprotein (Cooray et al., 2006) , whereas data on BUD are controversial (Cooray et al., 2006; Dilger et al., 2004) .
However, it is not yet known whether GC transporters operate in airway and lung cells.
The observed difference between BUD and CIC-AM rates of net ester formation are likely to result from equilibrium differences between ester synthesis and lipase/esterasecatalyzed hydrolysis. It cannot be excluded that these differences are due to different enzymes regulating esterification and/or hydrolysis of these two GCs, although ACAT seems to be involved in the esterification of both BUD and CIC-AM as cyclandelate (ACAT inhibitor) reduced the initial formation of both BUD and CIC-AM esters.
Furthermore, the hydrolysis of GC esters is a relatively stereoselective process (Hochberg et al et al., 1991) , and hydrolysis of BUD esters may be decelerated by the steric hindrance of the acetal group at 16α-and 17α-carbons. Contrariwise, a rapid hydrolysis of enzymatically accessible corticosterone esters (Hochberg et al., 1991) and cortisol esters (Dr. A. Tunek, AstraZeneca, personal communication) may explain why little esters of corticosterone and cortisol are detected, and why biological activity of these endogenous GCs is not dependent on ester formation.
Rapid formation of BUD esters in the airways and their slow hydrolysis contribute not only to prolong airway retention and activity (resulting in once daily efficacy; Campbell et al., 1991; Jones et al., 1994; Banov et al., 2001; Selroos et al., 2004) , but probably also to high airway selectivity (Edsbäcker and Jendbro, 1998; Miller-Larsson et al., 2000; Jendbro and Johansson, 2002) . This is because: i) esterification of inhaled BUD in the airway tissue retards BUD absorption into blood circulation, and ii) BUD esterification occurs to a much lower extent in skeletal muscles (10-15%) than in the airways (more than 50%), and does not occur in plasma (Miller-Larsson et al., 1999; Jendbro et al., 2001 ). Importantly, the results of pharmacokinetic and pharmacodynamic modelling suggest that the faster the formation of esters in the airways and slower their hydrolysis, the greater the airway selectivity of inhaled GCs (Jendbro and Johansson, 2002) . Indeed, we have earlier shown that after 4 days of repeated intratracheal instillation of BUD into rats, the total tissue concentration of BUD over 24 hours was 20-40-fold greater in trachea than in skeletal muscles and plasma, while respective ratios for CIC were 2-fold lower than for BUD (Gullstrand et al., 2005) . Thus, although inhaled CIC is reported to have a high airway selectivity, according to the results of this study this is unlikely to be due to airway esterification of CIC-AM.
